Dense deposit disease is a rare chronic glomerular condition. First-line management centres on two measurable, targetable parameters — blood pressure and urinary protein excretion — which are central to slowing renal disease progression.

Treatment Targets

The primary clinical goals are reduction of proteinuria and controlled blood pressure. Reaching these endpoints is the benchmark for first-line therapeutic success in dense deposit disease.

Proteinuria reduction Blood pressure control

Approach — Partial Overview

First-line management involves aggressive blood pressure control combined with targeted reduction of proteinuria. A specific class of antihypertensive agents is considered the anchor of first-line treatment in this setting. Depending on the individual metabolic picture, additional agents from a separate drug class may also be considered. The complete agent selection, sequencing, and monitoring criteria are available in the full structured protocol.

References

DOI: 10.1681/ASN.2007030356

Nonspecific measures that are effective in slowing progression of numerous chronic glomerular diseases include aggressive BP control and reduction of proteinuria.
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type 1 receptor blockers are first-line agents to decrease proteinuria, improve renal hemodynamics, and possibly limit leukocyte infiltration in the kidney.
Although not widely used in children, in the presence of hyperlipidemia, lipid-lowering agents such as hydroxymethylglutaryl CoA reductase inhibitors may also delay progression of renal disease, correct endothelial cell dysfunction, and alter long-term atherosclerotic risks.

View source ↗

Treatment of Dense Deposit Disease: Aggressive Blood Pressure Control and Proteinuria Reduction

References